Gemfibrozil Tablet
Product Images NDC 50090-5808

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 50090-5808). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

Adverse reactions text panel listing probable causal relationships and not established causal relationships for Gemfibrozil tablets 600 mg by A-S Medication Solutions. Side effects affecting multiple systems including cardiac, gastrointestinal, central nervous, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary are detailed, including conditions like cholestatic jaundice, dizziness, myopathy, increased liver enzymes, anemia, angioedema, and rash.*

FDA Label Image

Adverse Reactions (Adv Reactions)

A data table comparing the frequency in percent of various adverse events in subjects taking Gemfibrozil versus placebo. Events listed include gastrointestinal reactions, dyspepsia, abdominal pain, acute appendicitis, atrial fibrillation, diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation, and headache, with incidence percentages for both groups.*

FDA Label Image

Struct (Structure Gemfibrozil)

Chemical structure of Gemfibrozil, illustrating its aromatic ring with two methyl groups and a side chain containing an ether linkage and a carboxylic acid functional group, as shown in the label for GEMFIBROZIL 600 mg tablet by A-S Medication Solutions.*

FDA Label Image

Table1 (Table 1)

Table titled 'Reduction in CHD Rates (events per 1000 patients) by Baseline Lipids in the Helsinki Heart Study, Years 0-5'. It compares incidence of events between placebo (P) and Gemfibrozil (G) groups across different lipid baseline categories, showing differences in event rates including fatal and nonfatal myocardial infarctions plus sudden cardiac deaths per 1000 patients in 5 years.*

FDA Label Image

Table2 (Table 2)

A data table titled 'Table II' displaying cardiac events and all-cause mortality rates (events per 1000 patients) during a 3.5-year open-label follow-up to the Helsinki Heart Study. It compares six groups (Placebo and Gemfibrozil combinations) with sample sizes, showing cardiac event and mortality rates, alongside a footnote explaining group designations based on randomization and drug use during follow-up.*

FDA Label Image

Table3 (Table 3)

A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0-8.5' comparing gemfibrozil and placebo groups. It lists event counts at study start, hazard ratios for gemfibrozil versus placebo, and confidence intervals for hazard ratios across four events: cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality, with footnotes explaining analysis methods and definitions.*

FDA Label Image

Label Image (Lbl500905808)

GEMFIBROZIL 600 mg oral tablets label from A-S Medication Solutions. The label states each tablet contains 600 mg of gemfibrozil. Packaging includes 60 tablets. Storage instructions specify keeping at 68 to 77 degrees Fahrenheit in a tightly closed container protected from light and humidity. The label also shows the product NDC 50090-5808.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.